---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-336772"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2026-08-06T11:45:16+00:00"
generated_at: "2026-08-06T11:50:07.523462+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Intellia reports positive Phase 3 HAELO data for lonvo-z; BLA submission expected H2 2026

## Summary
- Phase 3 HAELO trial met primary endpoint: lonvo-z reduced HAE attacks by 87% vs placebo (p<0.0001); mean monthly attack rate 0.26 vs 2.10.
- 62% of lonvo-z patients attack-free and therapy-free for 6-month efficacy period vs 11% placebo; all key secondary endpoints met (p<0.0001).
- Cash, cash equivalents and marketable securities $628.4M as of June 30, 2026, after $195M public offering; funds operations at least into 2028.
- Net loss $106.6M in Q2 2026 vs $101.3M in Q2 2025; R&D expenses $82.6M, G&A expenses $37.8M due to commercial buildout.
- Enrollment reinitiated in nex-z Phase 3 trials; genomic analysis identified HLA allele linked to liver transaminase elevations; HLA genotyping to be provided.

## SEC filing metadata
- accession: 0001193125-26-336772
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2026-08-06T11:45:16+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312526336772/0001193125-26-336772-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312526336772/ntla-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-336772
- JSON: https://secwatch.observer/filing/0001193125-26-336772.json
- Plain text: https://secwatch.observer/filing/0001193125-26-336772.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.